You are here

CANCER THERAPEUTICS LABORATORIES, INC.

Company Information
Address
2011 ZONAL AVENUE, HMR205
LOS ANGELES, CA 90089
United States



Information

UEI: KS2BU4J2PHE3

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. OTHER FUNCTIONS SBIR PHASE II TOPIC 275, GENERIC ERBITUX FOR TREATMENT OF EGFR+ CANCER

    Amount: $2,479,561.00

    As a continuation of our Phase I SBIR contract with the NCI, this Phase II application is directed towards the further development of a biosimilar Erbitux antibody, designated ch225, for the immunothe ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  2. Not Available

    Amount: $299,456.00

    In the last decade, monoclonal antibody immunotherapy has established itself as a front-line treatment of human cancer. One such antibody, Erbituz (cetuzimab), has been used to treat epidermal growth ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  3. Monoclonal Antibodies Against T-Regulatory Cells

    Amount: $639,999.00

    DESCRIPTION (provided by applicant): Immunotherapy is a powerful therapeutic modality that has great potential for the treatment of cancer. Considering the lack of options which exist for patients w ...

    STTRPhase I2004Department of Health and Human Services National Institutes of Health
  4. Monoclonal Antibodies Against T-Regulatory Cells

    Amount: $639,999.00

    DESCRIPTION (provided by applicant): Immunotherapy is a powerful therapeutic modality that has great potential for the treatment of cancer. Considering the lack of options which exist for patients w ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government